CA2486105A1 - Configurations differentielles d'expression genetique permettant la prevision de chimiosensibilite et de chimioresistance au docetaxel - Google Patents

Configurations differentielles d'expression genetique permettant la prevision de chimiosensibilite et de chimioresistance au docetaxel Download PDF

Info

Publication number
CA2486105A1
CA2486105A1 CA002486105A CA2486105A CA2486105A1 CA 2486105 A1 CA2486105 A1 CA 2486105A1 CA 002486105 A CA002486105 A CA 002486105A CA 2486105 A CA2486105 A CA 2486105A CA 2486105 A1 CA2486105 A1 CA 2486105A1
Authority
CA
Canada
Prior art keywords
seq
docetaxel
nucleic acids
sample
probes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002486105A
Other languages
English (en)
Inventor
Jenny Chee Ning Chang
Peter O'connell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2486105A1 publication Critical patent/CA2486105A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des profils différentiels d'expression génétiques permettant la détermination de la sensibilité au docetaxel. L'invention identifie des profils moléculaires dans des cancers primitifs du sein qui semblent prédire une sensibilité ou une insensibilité au docetaxel. La présente invention a également trait à des procédés permettant la prédiction de la sensibilité au docetaxel ainsi que des jeux ordonnés d'échantillons utiles dans la détermination de la sensibilité au docetaxel.
CA002486105A 2002-05-17 2003-05-16 Configurations differentielles d'expression genetique permettant la prevision de chimiosensibilite et de chimioresistance au docetaxel Abandoned CA2486105A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38114102P 2002-05-17 2002-05-17
US60/381,141 2002-05-17
PCT/US2003/015691 WO2004035805A2 (fr) 2002-05-17 2003-05-16 Configurations differentielles d'expression genetique permettant la prevision de chimiosensibilite et de chimioresistance au docetaxel

Publications (1)

Publication Number Publication Date
CA2486105A1 true CA2486105A1 (fr) 2004-04-29

Family

ID=32107802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002486105A Abandoned CA2486105A1 (fr) 2002-05-17 2003-05-16 Configurations differentielles d'expression genetique permettant la prevision de chimiosensibilite et de chimioresistance au docetaxel

Country Status (10)

Country Link
US (1) US20040018527A1 (fr)
EP (1) EP1576177A4 (fr)
JP (1) JP2006505256A (fr)
AU (1) AU2003301458A1 (fr)
CA (1) CA2486105A1 (fr)
IL (1) IL165240A0 (fr)
MX (1) MXPA04011424A (fr)
RU (1) RU2004136990A (fr)
WO (1) WO2004035805A2 (fr)
ZA (1) ZA200409189B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465542B2 (en) * 2002-10-15 2008-12-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining risk of treatment toxicity
WO2005118858A1 (fr) * 2004-05-28 2005-12-15 Board Of Regents, The University Of Texas System Prédicteurs multigènes de la réponse à une chimiothérapie
JP5299885B2 (ja) * 2005-08-12 2013-09-25 学校法人日本大学 Ｈｃｖ陽性肝細胞癌の発癌・再発に関連する遺伝子
US20080085243A1 (en) * 2006-10-05 2008-04-10 Sigma-Aldrich Company Molecular markers for determining taxane responsiveness
JPWO2011065533A1 (ja) * 2009-11-30 2013-04-18 国立大学法人大阪大学 乳癌術前化学療法に対する感受性の判定方法
US20130130928A1 (en) 2010-04-08 2013-05-23 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5645988A (en) * 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
WO1994017208A1 (fr) * 1993-01-21 1994-08-04 President And Fellows Of Harvard College Methodes et trousses de diagnostic faisant appel aux promoteurs de stress des mammiferes pour determiner la toxicite d'un compose
US6136587A (en) * 1995-07-10 2000-10-24 The Rockefeller University Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof
US20020006613A1 (en) * 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies
US6107034A (en) * 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US6759238B1 (en) * 1999-03-31 2004-07-06 St. Jude Children's Research Hospital Multidrug resistance associated proteins and uses thereof
WO2001051667A2 (fr) * 2000-01-14 2001-07-19 Integriderm, L.L.C. Jeux ordonnes d'echantillons d'acides nucleiques informatifs et methodes de production associees
AU2001245295A1 (en) * 2000-02-17 2001-08-27 Millennum Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001073430A2 (fr) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. Compositions et procedes d'identification, evaluation, prevention, et traitement de cancers humains
WO2001079556A2 (fr) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions et methodes destines a l'identification, l'evaluation, la prevention, et la therapie de cancers humains
WO2001084156A2 (fr) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. Compositions et techniques de definition, d'evaluation, de prevention et de therapie des cancers chez l'homme
US6368806B1 (en) * 2000-10-05 2002-04-09 Pioneer Hi-Bred International, Inc. Marker assisted identification of a gene associated with a phenotypic trait
AU2002318374A1 (en) * 2001-06-21 2003-01-08 Baylor College Of Medicine Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway

Also Published As

Publication number Publication date
US20040018527A1 (en) 2004-01-29
IL165240A0 (en) 2005-12-18
MXPA04011424A (es) 2005-02-17
AU2003301458A1 (en) 2004-05-04
ZA200409189B (en) 2006-03-29
WO2004035805A3 (fr) 2006-02-16
JP2006505256A (ja) 2006-02-16
RU2004136990A (ru) 2005-08-10
WO2004035805A2 (fr) 2004-04-29
EP1576177A2 (fr) 2005-09-21
EP1576177A4 (fr) 2007-12-26

Similar Documents

Publication Publication Date Title
Solovieva et al. Possible association of interleukin 1 gene locus polymorphisms with low back pain
JP2009543552A5 (fr)
WO2005054508A2 (fr) Profilage de l'expression des genes dans le cancer du colon par microreseaux d'adn et correlation avec des parametres de survie et histocliniques
CA2527285A1 (fr) Marqueurs de l'expression genetique permettant de predire la reponse une chimiotherapie
WO2012170704A2 (fr) Procédés et compositions pour la prédiction de l'activité d'un modulateur du récepteur x des rétinoïdes
AU2013301606B2 (en) Genetic markers for predicting responsiveness to FGF-18 compound
WO2008007072A2 (fr) Procédé d'inhibition cellulaire
AU2013301607B2 (en) Prognosis biomarkers in cartilage disorders
WO2015114146A1 (fr) Procédé permettant de prédire la réponse à une thérapie et/ou une chimiothérapie à base d'anti-her2 chez des patientes atteintes d'un cancer du sein
CA2486105A1 (fr) Configurations differentielles d'expression genetique permettant la prevision de chimiosensibilite et de chimioresistance au docetaxel
JP2005524388A (ja) パクリタキセル応答性予測の一塩基多型及びそれらの組合せ
KR20160082028A (ko) 방광암 예후 진단 마커로서 ｒｓｐｈ９의 용도
CA2422305A1 (fr) Diagnostics du cancer colorectal
KR20050016410A (ko) 도세탁셀 약제민감성 및 약제내성을 예측하는 특징적인유전자 발현 패턴
WO2010076887A1 (fr) Biomarqueurs prédictifs utiles pour une thérapie anticancéreuse à médiation par un inhibiteur de wee1
CA2525179A1 (fr) Equation genetique utilisee pour diagnostiquer une polyarthrite rhumatoide
US20120157342A1 (en) Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
KR101141546B1 (ko) Ａｎｋｒｄ15, ｈｐｄ, ｐｓｍｄ9, ｗｄｒ66, ｇｐｃ6, ｐａｘ9, ｌｒｒｃ28, ｔｎｓ4, ａｘｌ, 및 ｈｎｒｐｕｌ1 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법
US20100015620A1 (en) Cancer-linked genes as biomarkers to monitor response to impdh inhibitors
KR102464776B1 (ko) 여성형 탈모증 관련 유전자 다형성 마커 및 이의 용도
KR102562955B1 (ko) 폐 기능 저하 위험 예측용 단일염기다형성 및 이의 용도
WO2006055676A2 (fr) Base moleculaire pour identifier une resistance chimiotherapique dans des tumeurs humaines et traitement associe
KR101139360B1 (ko) Ｐｒｋｃｉ, ｍａｐｋ10, ｓｐｐ1, ｉｑｇａｐ2, ｆｇｆｒ4, ｎｏｔｃｈ4, ｈｌａ-ｄｒａ, ｈｌａ-ｄｏａ, ｔｈｂｓ2, ｄｆｎａ5, ｔｂｘａｓ1, ｔｎｋｓ, ｃｄｈ17, ｕｂｒ5, ｋｉａａ0196, 및 ｎｓｍｃｅ2 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법
KR20130100640A (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
KR20220034956A (ko) 유전자 다형성 마커 기반 여성형 탈모증 위험도 예측 모델

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued